Cue Biopharma, a clinical-stage biotech focused on immunological disorders, entered into a securities purchase agreement on July 9, 2026, with a group of accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. The private placement covers 1,418,071 shares of common stock priced at $33.21 per share, plus pre-funded warrants to purchase up to 87,500 additional shares at $33.209 per warrant. Gross proceeds total approximately $50 million, with closing expected on July 13.
The pre-funded warrants carry a nominal exercise price of $0.001 per share and are immediately exercisable on a cashless basis. They include standard beneficial ownership blockers, initially set at 4.99% or 9.99% of outstanding shares at the holder's election, with the option to raise that ceiling to 19.99% after a 61-day notice period. In the event of a fundamental transaction consisting solely of cash or marketable securities, the warrants will be deemed exercised in full immediately before the deal closes.
The company intends to direct the net proceeds toward further clinical development and general corporate purposes. Under a related registration rights agreement, Cue Biopharma must file a resale registration statement for the securities within 30 days of closing and use reasonable best efforts to have it declared effective within 60 days if the SEC reviews the filing, or within five business days if the SEC confirms no review.
Going concern risk remains
Buried within the cautionary language of the 8-K filing is an acknowledgment that the company continues to carry a going concern determination. The forward-looking statements section warns that Cue Biopharma may not have sufficient capital on hand to continue operations beyond the next twelve months and that its ability to obtain adequate financing in the future remains uncertain. The $50 million infusion provides additional runway, but the filing itself does not state that the going concern issue has been resolved.
Equity grants to executives and directors
In a separate disclosure, the company reported that its board granted an aggregate of 1,064,492 restricted stock units to employees and executive officers on July 9. CEO Shao-Lee Lin received 655,074 RSUs, Chief Legal and Compliance Officer Sumita Ray received 109,178 RSUs, and Principal Accounting Officer Michael Meluzio received 81,884 RSUs. Each non-employee director received a one-time grant of 21,800 RSUs vesting in three equal annual installments. The grants were made under the company's 2026 Stock Incentive Plan, which shareholders approved at the most recent annual meeting.
The private placement and equity awards arrive shortly after a board transition in early June that added former CEO Daniel Camardo and former CFO Viola Meehan as directors, and follow a separate $28 million financing completed in May alongside the appointment of Lin as president and CEO.